A March Decision That Could Change Protalix BioTherapeutics Outlook

2026-02-01 21:27:08 ET

Thesis

As you know, Protalix Bio Therapeutics ( PLX ) has just announced some news that should serve as a very positive regulatory and clinical milestone for their Fabry disease treatment in Europe. You see, the EMA’s Committee for Medicinal Products for Human Use ( CHMP ) has just issued a positive opinion recommending approval of a dosing regimen of Elfabrio, which can take place every-four-weeks (E4W) for stable adult patients. I think this could potentially transform how enzyme replacement therapy is delivered if the European Commission goes on to confirm this decision by March. It would mean that any eligible patients who now need infusions every two weeks could potentially halve their treatment visits, which would be a massive improvement for patients. It would, of course, reduce physical, emotional, and logistical burden whilst still maintaining the same safety and efficacy. Shares traded up about 14% on the news ....

Read the full article on Seeking Alpha

For further details see: